Side Effects of Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis-C

この論文をさがす

抄録

Objective The aim of this study was to elucidate the side effects after combination therapy of peginterferon and ribavirin for Japanese patients with chronic hepatitis C.<br> Methods Inclusion criteria were HCV-genotype 1b and serum HCV RNA level of >100 KIU/ml. Six hundred and twelve patients were received combination therapy and enrolled in this non-randomized prospective cohort study. Patients were monitored until the discontinuation of combination therapy based on treatment-related side effects. The percentage of each medication actually taken during treatment was calculated.<br> Results Sixty-eight patients were stopped the combination therapy due to side effects. The cumulative discontinuation rate due to side effects of therapy was 8.4% at 0.5 year and 14.9% at one year. Discontinuation rate due to side effects was high with statistically significant in the following cases: 1) patients ≥65 years, 2) patients who had diabetes. Sustained viral response (SVR) was 17.6% (12/68) in the discontinuation group. In the discontinuation group, when the percentage of both peginterferon and ribavirin actually taken during treatment was ≥60%, SVR was 31% (9/29). On the other hand, when the percentage of each medication actually taken during treatment was <60%, SVR was 7.7% (3/39). In the discontinuation group, patients with adherence of >60% to the total of scheduled dose tended to have a high SVR compared to those with ≤60% adherence to the total of scheduled dose.<br> Conclusion In combination therapy, patient age and complications of patient are important factors contributing to the safety. In the discontinuation group, patients with adherence of >60% to the total of scheduled dose tend to have a high SVR.<br>

収録刊行物

  • Internal Medicine

    Internal Medicine 46 (22), 1827-1832, 2007

    一般社団法人 日本内科学会

被引用文献 (14)*注記

もっと見る

参考文献 (16)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ